Logotype for Oxford Biomedica plc

Oxford Biomedica (OXB) investor relations material

Oxford Biomedica H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Oxford Biomedica plc
H1 2025 earnings summary23 Sep, 2025

Executive summary

  • Achieved strong commercial and operational progress in H1 2025, with significant order growth and increased revenue visibility driven by high demand for CDMO services across all vector types and late-stage client activities.

  • Revenue increased 44% year-over-year to £73.2M, with significant improvements in profitability and EBITDA loss narrowing by £12M to £8.3M.

  • Expanded global footprint and manufacturing capabilities in the UK, US, and France, with strategic investments and manufacturing optimization initiatives underway.

  • Strengthened balance sheet with a £60M equity placement and a new $125M loan facility, enhancing financial flexibility.

Financial highlights

  • Total revenues rose 44% to £73.2M in H1 2025 from £50.8M in H1 2024, driven by robust demand for CDMO services.

  • Manufacturing services revenue increased 25% to £34.4M; development services up 48% to £28.5M.

  • Contracted client orders signed in 2025 totaled £149M, up from £56M in H1 2024; revenue backlog at June 30 was £222M, rising to £241M by August 31.

  • Cash position at period end was £53.9M, increasing to £113.7M post-period after equity raise and loan facility.

  • Operating EBITDA loss improved to £8.3M from £20.3M last year; operating cash outflow reduced to £4.8M from £48.6M.

Outlook and guidance

  • 2025 revenue guidance reiterated at £160M–£170M, with low single-digit million pounds operating EBITDA profitability expected.

  • 2026 revenue expected at £220M–£240M, representing 35–39% CAGR from 2023–2026.

  • Long-term revenue growth targeted at 25–30% annually for 2027 and 2028, with EBITDA margins approaching 30%.

  • Over £171M of 2025 revenues already covered by contracted orders.

  • Funding in place to expand global manufacturing capabilities, including US GMP capacity, to meet rising client demand.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Oxford Biomedica earnings date

Logotype for Oxford Biomedica plc
CMD 20255 Jan, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Oxford Biomedica earnings date

Logotype for Oxford Biomedica plc
CMD 20255 Jan, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development and bioprocessing of cell and gene therapy products in Europe and internationally. The company's products are designed to treat diseases by replacing or enhancing a patient's defective genes with normal or healthy copies in order to restore or correct its function. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage